DENTSPLY SIRONA (NASDAQ:XRAY) Sets New 1-Year Low – Here’s What Happened

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) reached a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $8.38 and last traded at $8.3360, with a volume of 1,107,926 shares traded. The stock had previously closed at $8.51.

Analyst Upgrades and Downgrades

XRAY has been the subject of a number of analyst reports. BMO Capital Markets cut their target price on DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating for the company in a research note on Thursday, September 17th. Leerink Partners decreased their price target on DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating on the stock in a research note on Wednesday. Piper Sandler dropped their price objective on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Friday, October 9th. Barclays upped their price objective on DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a report on Monday, August 24th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $12.92.

DENTSPLY SIRONA Stock Up 4.6%

The company has a debt-to-equity ratio of 1.48, a current ratio of 1.63 and a quick ratio of 1.07. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -3.21, a price-to-earnings-growth ratio of 1.08 and a beta of 0.87. The firm’s 50-day simple moving average is $10.19 and its two-hundred day simple moving average is $11.05.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.17. The company had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The company’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same period last year, the firm earned $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts predict that DENTSPLY SIRONA Inc. will post 1.39 EPS for the current fiscal year.

Hedge Funds Weigh In On DENTSPLY SIRONA

Hedge funds and other institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company purchased a new position in shares of DENTSPLY SIRONA in the second quarter valued at $1,956,000. BlackRock Inc. acquired a new position in shares of DENTSPLY SIRONA during the 2nd quarter worth $283,405,000. Paradigm Capital Management Inc. NY acquired a new position in shares of DENTSPLY SIRONA during the 2nd quarter worth $39,775,000. Bank of New York Mellon Corp acquired a new position in shares of DENTSPLY SIRONA during the 2nd quarter worth $16,408,000. Finally, Edmond DE Rothschild Holding S.A. purchased a new stake in shares of DENTSPLY SIRONA in the 2nd quarter worth about $47,780,000. 95.70% of the stock is owned by institutional investors and hedge funds.

DENTSPLY SIRONA Company Profile

Dentsply Sirona is a global dental products and technologies company that develops, manufactures and markets solutions for dental professionals, laboratories and patients. Its portfolio includes consumable products, dental equipment and digital technologies used in preventive, restorative, endodontic, orthodontic, implant and prosthetic dentistry.

The company offers dental treatment centers, imaging systems, CAD/CAM systems, intraoral scanners, milling and 3D-printing solutions, instruments, endodontic files and equipment, restorative materials, dental implants, prosthetic components and orthodontic products.